US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

18.54

-0.0800-0.43%

Volume:381.71K

Turnover:7.09M

Market Cap:2.42B

PE:15.60

High:18.78

Open:18.64

Low:18.48

Close:18.62

Loading ...

Overview Company News Filings

Provident Financial (PFS) Soars 6.1%: Is Further Upside Left in the Stock?

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

American Battery Technology Company Completes Additional Drill Program to Progress Mission to Increase American Critical Mineral Production at its Nevada Lithium Project

European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings

ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

TransMedics Group And 2 Other Stocks That May Be Trading Below Estimated Value

Simply Wall St.

3 Stocks That May Be Trading Up To 36.1% Below Their Intrinsic Value Estimates

Simply Wall St.

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Press Release: Provident Bank Elevates Tara Brady to Chief Experience Officer to Drive Customer Experience and Brand Growth

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

ACCESS Newswire

Press Release: TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Provident Financial Services, Inc. Schedules First Quarter Earnings Conference Call

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Cavalier Resources’ Revised PFS Indicates Strong Financial Prospects for Crawford Gold Project

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives

Hot Chili Announces PFS for Huasco Water & MOU for Seawater Supply to Costa Fuego

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PFS/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":18.54,"timestamp":1752867450093,"preClose":18.62,"halted":0,"volume":381710,"delay":0,"floatShares":126185309,"shares":130659942,"eps":1.188092,"marketStatus":"Trading","change":-0.08,"latestTime":"07-18 15:37:32 EDT","open":18.64,"high":18.78,"low":18.48,"amount":7094405.56692,"amplitude":0.016112,"askPrice":18.55,"askSize":202,"bidPrice":18.54,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.188092,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1752868800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":18.62,"dividendRate":0.05178,"preHourTrading":{"tag":"盘前","latestPrice":18.62,"preClose":18.62,"latestTime":"08:38 EDT","volume":1,"amount":18.62,"timestamp":1752842292170},"postHourTrading":{"tag":"盘后","latestPrice":18.62,"preClose":18.62,"latestTime":"17:25 EDT","volume":373167,"amount":6948369.54,"timestamp":1752787505322},"volumeRatio":0.543561,"impliedVol":0.0604,"impliedVolPercentile":0.08},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126185309,"roa":"0.77%","roe":"6.77%","lyrEps":1.053397,"volumeRatio":0.543561,"shares":130659942,"dividePrice":0.96,"high":18.78,"amplitude":0.016112,"preClose":18.62,"low":18.48,"week52Low":14.335,"pbRate":"0.91","psRate":"3.46","week52High":22.24,"institutionHeld":0.6776,"latestPrice":18.54,"committee":-0.337748,"eps":1.188092,"divideRate":0.05178,"volume":381710,"delay":0,"ttmEps":1.188092,"open":18.64,"prevYearClose":18.87,"prevWeekClose":18.54,"prevMonthClose":17.53,"prevQuarterClose":17.53,"fiveDayClose":18.54,"twentyDayClose":16.14,"sixtyDayClose":16.01,"earningDate":1753286400000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526598229","title":"Provident Financial (PFS) Soars 6.1%: Is Further Upside Left in the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526598229","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526598229?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:54","pubTimestamp":1744286040,"startTime":"0","endTime":"0","summary":"Provident Financial  shares ended the last trading session 6.1% higher at $15.90. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8.4% loss over the past four weeks.Provident Financial witnessed a notable surge in its stock price following Trump’s announcement on April 9, 2025, of a 90-day pause on reciprocal tariffs for most trading partners, excluding China. The tariff pause reduced immediate fears of a trade war, fostering a more favorable economic outlook. This optimism boosted investor confidence in the financial sector stocks, like PFS.This holding company for The Provident Bank is expected to post quarterly earnings of $0.47 per share in its upcoming report, which represents a year-over-year change of +9.3%. Revenues are expected to be $209.45 million, up 83% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/provident-financial-pfs-soars-6-115400357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BRKL","PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2526550198","title":"OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans","url":"https://stock-news.laohu8.com/highlight/detail?id=2526550198","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526550198?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:42","pubTimestamp":1744285320,"startTime":"0","endTime":"0","summary":"Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor, delayed pulmonary metastases and prolonged overall survival of greater than 500 days in 5 out of 15 dogs.Data from new publication in the journal \"Molecular Therapy\" show OST-HER2 induces strong innate and cytotoxic immune responses beginning at the 1st dose of 3 dose regimen, that correlate with prevention of metastasis and long-term survival in dogs with resected primary osteosarcoma.Additionally, the Company announced the publication of positive data in the journal \"Molecular Therapy\" entitled \"Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2\" demonstrated the correlation of innate and adaptive immune responses to OST-HER2, with prevention of metastasis and long-term survival benefit when used in the a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-announces-positive-data-114200323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4195","BK4017","ADC","DC","BK4080","OST","OSTX","PFS","BK4211","BK4148","BK4231"],"gpt_icon":1},{"id":"2526399577","title":"FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2526399577","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526399577?lang=en_us&edition=fundamental","pubTime":"2025-04-09 22:58","pubTimestamp":1744210733,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration  on Tuesday approved Bristol Myers Squibb& Co’s  Opdivo plus Yervoy as a first-line treatment of adult and pediatric patients  with unresectable or metastatic microsatellite instability-high  or mismatch repair deficient  colorectal cancer .The approval comes ahead of over two months of the June 23, 2025, Prescription Drug User Fee Act goal date.Also Read: Europe Approves Bristol Myers’ Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer. Opdivoas a single agent, or in combination withYervoy, was previously granted accelerated approval in MSI-H/dMMR CRC adult and pediatric patients  that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.Price Action: BMY stock is down 5.31% at $50.25 at the last check on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-bristol-myers-opdivo-145853592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505439.SGD","LU0114720955.EUR","LU0882574055.USD","IE00B2B36J28.USD","LU1670711040.USD","BK4588","BMY","LU1291159041.SGD","BK4211","BK4213","LU1571399168.USD","LU1670710661.SGD","LU2133065610.SGD","LU0985481810.HKD","BK4532","IE00BFTCPJ56.SGD","LU1868836757.USD","PFS","BK4559","LU0321505868.SGD","LU0061475181.USD","LU0456855351.SGD","LU1032466523.USD","LU1868837136.USD","LU1868836914.USD","BK4126","IE00BSNM7G36.USD","LU0306806265.USD","MYE","ORR","BK4534","LU0225284248.USD","LU2125154778.USD","LU1718418525.SGD","LU1670711123.USD","LU2360032135.SGD","IE00BFXG1179.USD","LU1868836591.USD","LU0225771236.USD","LU0266512127.USD","LU1093756168.USD","LU0306807586.USD","BK4585","LU2242646821.SGD","CRC","LU1323610961.USD","BK4195","IE00BJJMRZ35.SGD","LU1989771016.USD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2526840536","title":"U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840536","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840536?lang=en_us&edition=fundamental","pubTime":"2025-04-09 03:36","pubTimestamp":1744140960,"startTime":"0","endTime":"0","summary":"Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo monotherapy across all lines of therapy 1. The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date. In the CheckMate-8HW trial, Opdivo plus Yervoy demonstrated a 38% reduction in the risk of disease progression or death vs. Opdivo monotherapy in immunotherapy-nave patients across all lines of therapy .1 Assessing the dual primary endpoint of PFS, the trial demonstrated that median PFS was not reached with Opdivo plus Yervoy  and was 39.3 months with Opdivo monotherapy .1 PFS rates at 12-, 24-, and 36-months were also numerically higher","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-approves-193600303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1261432733.SGD","IE0002141913.USD","IE0009355771.USD","TEN","LU1032466523.USD","BK4124","LU1989771016.USD","LU0985481810.HKD","LU1670711040.USD","LU2242646821.SGD","BK4195","LU0237698245.USD","IE00BFTCPJ56.SGD","LU0225284248.USD","LU1670710588.SGD","BK4132","LU1323610961.USD","LU1585245621.USD","BK4006","OS","LU0061475181.USD","BK4211","IE00B2B36J28.USD","BK4532","LU0868494617.USD","LU0225771236.USD","HCC","LU1868836757.USD","LU1093756168.USD","BK4534","LU1670710661.SGD","PFS","BK4144","ORR","LU1868837300.USD","HSCT","LU0114720955.EUR","LU1718418525.SGD","LU1868837136.USD","BMY","CRC","LU1093756325.SGD","LU2133065610.SGD","LU1074936037.SGD","LU2242652126.USD","VOD","CRT","LU1670711123.USD","IE00BSNM7G36.USD","BK4581"],"gpt_icon":0},{"id":"2525133578","title":"American Battery Technology Company Completes Additional Drill Program to Progress Mission to Increase American Critical Mineral Production at its Nevada Lithium Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2525133578","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525133578?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:45","pubTimestamp":1744119900,"startTime":"0","endTime":"0","summary":"Completion of 8 HQ Core Hole Drill Program to accelerate the company’s efforts to commercialize the Tonopah Flats Lithium Project in support of 'Immediate Measures to Increase American Mineral Production', a Presidential Executive Order. American Battery Technology Company's Tonopah Flats Lithium Project - Drill Program 4. American Battery Technology Chief Mineral Resource Officer Scott Jolcover, pictured left, and CEO Ryan Melsert, pictured right, inspect core samples collected from its Tonopah Flats Lithium Project in Nevada as part of its fourth drill program.  The completion of this drill program marks an important milestone in the company’s effort to accelerate the commercialization of its domestic lithium resource.This map identifies the 8 HQ core drill holes where samples were collected as part of  American Battery Technology Company completed fourth drill program at its Tonopah Flats Lithium project in central Nevada.  Core samples collected are currently being assayed, and the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057723/0/en/American-Battery-Technology-Company-Completes-Additional-Drill-Program-to-Progress-Mission-to-Increase-American-Critical-Mineral-Production-at-its-Nevada-Lithium-Project.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","PFS","BK4211","LU2065732104.USD","PRGS","GT","ABAT","BK4195","BK4119","BK4168","BK4097","ABMLD"],"gpt_icon":0},{"id":"2525691739","title":"European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2525691739","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525691739?lang=en_us&edition=fundamental","pubTime":"2025-04-05 02:02","pubTimestamp":1743789775,"startTime":"0","endTime":"0","summary":"The European Commission on Friday approved AstraZeneca Plc  and Daiichi Sankyo's Enhertu  as a monotherapy for a type of breast cancer.The approval covers adult patients with unresectable or metastatic hormone receptor -positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.Also Read: FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients. The approval is based on results from the DESTINY-Breast06 Phase 3 trial.In the trial,Enhertushowed a 38% reduction in the risk of disease progression or death versus chemotherapy in patients with chemotherapy-nave HR-positive, HER2-low metastatic breast cancer with a median progression-free survival  of 13.2 months versus 8.1 months.In the overall trial population, the median PFS was 13.2 months in patients randomized toEnhertucompare","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-drug-regulator-approves-astrazenecas-180255396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HR","BK4585","LU2236285917.USD","BK4500","LU2456880835.USD","OS","BK4211","LU2417539215.USD","PFS","BK4007","BK4203","AZN","LU2462157665.USD","BK4195","LU1829250122.USD","BK4008","BK4568","BK4097","BK4588","ALK","LU0889565916.HKD","BK4225","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2524220685","title":"ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524220685","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524220685?lang=en_us&edition=fundamental","pubTime":"2025-04-04 14:00","pubTimestamp":1743746400,"startTime":"0","endTime":"0","summary":"Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year. Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU earlier in the treatment of HR positive, HER2 low breast cancer and broadens the eligible patient population to those with HER2 ultralow disease. HR positive, HER2 negative is the most common breast cancer subtype, accounting for approximately 70% of all breast cancers.1 Despite being classified as HER2 negative, many of these tumors still have some level of HER2 expression. Currently, regardless of HER2 expression, endocrine-based therapies are widely used in the early lines of treatment for HR positive metastatic breast cancer. Following endocrine-based therapy, some patients discontinue treatment, and others are treated with conventional chemotherapy which is associated with poor response rates and outcomes.2,3,4,5. In the DESTINY-Breast06 trial, ENHERT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-approved-eu-first-her2-060000976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSKYF","BK4231","BK4225","BK4156","PFS","HR","PBD","DSNKY","BK4007","BK4211","ORR","ADC","BK4195","BK4203","BK4080"],"gpt_icon":0},{"id":"2524296253","title":"TransMedics Group And 2 Other Stocks That May Be Trading Below Estimated Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2524296253","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524296253?lang=en_us&edition=fundamental","pubTime":"2025-04-04 01:08","pubTimestamp":1743700082,"startTime":"0","endTime":"0","summary":"In recent days, the U.S. stock market has experienced significant volatility, with major indices like the Dow Jones and Nasdaq Composite seeing sharp declines following President Trump's announcement of new tariffs on imports. These developments have heightened concerns about inflation and economic growth, leading investors to reassess their strategies in a shifting landscape. In such uncertain times, identifying stocks that may be trading below their estimated value can provide opportunities for investors looking to strengthen their portfolios amidst broader market fluctuations.Top 10 Undervalued Stocks Based On Cash Flows In The United States. TransMedics Group's recent earnings report shows a strong recovery, with net income of US$35.46 million for 2024, reversing a prior year's loss. The stock is trading at US$73.11, significantly below its estimated fair value of US$130.7, suggesting undervaluation based on discounted cash flow analysis. Despite legal challenges alleging misleadin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transmedics-group-2-other-stocks-170802779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4114","BK4211","TMDX","LU2324357040.USD","BK4588","CINT","BK4220","LU2065731478.USD","AVPTW","ASB","LU0274383008.USD","BK4134","BK4585","PLMR","PFS","LU1046422090.SGD","BHLB","AVPT","BK4082","BK4195"],"gpt_icon":1},{"id":"2524253142","title":"3 Stocks That May Be Trading Up To 36.1% Below Their Intrinsic Value Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2524253142","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524253142?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:07","pubTimestamp":1743678470,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a turbulent phase marked by recent tariff announcements and volatile trading sessions, investors are keenly assessing opportunities that may arise from these fluctuations. In such an environment, identifying stocks potentially undervalued relative to their intrinsic value becomes crucial, as these could offer significant upside potential once market conditions stabilize.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Overview: Intuit Inc. offers financial management, compliance, and marketing products and services in the United States with a market cap of approximately $171.59 billion.Operations: The company's revenue segments include Pro-Tax at $594 million, Consumer at $4.45 billion, Credit Karma at $1.96 billion, and Global Business Solutions at $10.16 billion.Intuit is trading at US$620.91, below its estimated fair value of US$812.22, indicating potential undervaluation based on cash flows. Its earnings are projected to grow fa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-stocks-may-trading-36-110750631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","LU0006061336.USD","LU1169589451.USD","BHLB","IE00B19Z3B42.SGD","ODD","ASB","CINT","BK4211","BK4213","EQT","INTU","LU1169590202.USD","LU1046422090.SGD","BK4585","LU0274383008.USD","PFS","BK4505","IE0002270589.USD","IE00B7SZLL34.SGD","BK4588","BK4114","BK4220","BK4134","BK4195"],"gpt_icon":1},{"id":"2524449342","title":"Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2524449342","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524449342?lang=en_us&edition=fundamental","pubTime":"2025-04-03 03:00","pubTimestamp":1743620400,"startTime":"0","endTime":"0","summary":"It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met its primary goal. On the other hand, Axsome Therapeutics’ AXSM shares declined after announcing results from a study on major depressive disorder .Shares of Corcept Therapeutics Incorporated surged on March 31 after the company announced the success of the late-stage ROSELLA study.The phase III ROSELLA study evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer.Axsome Therapeutics announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder  with and without severe excessive daytime sleepiness .Nonetheless, in the prespecified subgroup of patients with severe EDS, treatment with solriamfetol led to greater improvements in depres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-cort-study-190000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","CORT","LU0321505868.SGD","AXSM","IE00BSNM7G36.USD","BK4534","BK4585","LU1585245621.USD","LU1323610961.USD","LU1868836591.USD","BMY","LU1868836757.USD","LU0321505439.SGD","LU1670711040.USD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU1670710588.SGD","LU1718418525.SGD","IE00BJT1NW94.SGD","LU2242646821.SGD","LU0566484027.USD","OS","LU2360032135.SGD","LU2125154935.USD","BK4532","LU1093756325.SGD","BK4007","BLUE","LU0985481810.HKD","LU1291159041.SGD","LU1670711123.USD","LU2242652126.USD","BK4578","LU0306807586.USD","BK4097","EXEL","LU2125154778.USD","IE00B2B36J28.USD","LU1670710661.SGD","BK4556","BK4588","LU0882574055.USD","BK4505","LU1571399168.USD","LU1093756168.USD","LU1074936037.SGD","LU1989771016.USD","LU0456855351.SGD","LU0306806265.USD","LU0225284248.USD"],"gpt_icon":1},{"id":"2524620984","title":"Press Release: Provident Bank Elevates Tara Brady to Chief Experience Officer to Drive Customer Experience and Brand Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2524620984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524620984?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:00","pubTimestamp":1743595200,"startTime":"0","endTime":"0","summary":"Provident Bank Elevates Tara Brady to Chief Experience Officer to Drive Customer Experience and Brand Growth. ISELIN, N.J., April 02, 2025  -- Provident Bank, a leading New Jersey-based financial institution, is pleased to announce that Tara Brady has been promoted to Senior Vice President, Chief Experience Officer , responsible for leading the bank's marketing and customer experience strategies, and ensuring seamless, customer-centric engagement across the organization. Ms. Brady will also focus on fostering deep collaboration and synergy between customer experience and employee experience. Since joining Provident, Ms. Brady has been instrumental in centralizing and enhancing the experience for customers. Her new role expands this work in support of the bank's growth throughout the region.Founded in Jersey City in 1839, Provident Bank is the oldest community-focused financial institution based in New Jersey and is the wholly owned subsidiary of Provident Financial Services, Inc. . Wit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","BK4087","PFS","BK4211","BK4195","BRC","CXO"],"gpt_icon":0},{"id":"2524115923","title":"CNS Pharmaceuticals Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524115923","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524115923?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:05","pubTimestamp":1743509100,"startTime":"0","endTime":"0","summary":"Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme  for treatment of brain malignancies. CNS Pharmaceuticals plans to engage the FDA and obtain feedback on the design of a study potentially focused on the registration of TPI 287 in recurrent GBM in 2025.The Company recently reported results from the primary analysis of Berubicin in second line treatment of glioblastoma multiforme . The trial compared Berubicin to Lomustine, a current standard of care in GBM. The analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint. However, although the trial was","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-reports-full-2024-120500175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","PFS","BK4135","CNS","OS","BK4007","BK4211","CNSP","BK4097"],"gpt_icon":0},{"id":"2524190796","title":"Press Release: TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524190796","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524190796?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:00","pubTimestamp":1743508800,"startTime":"0","endTime":"0","summary":"Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda. MCC Phase 3 trial to be conducted under Special Protocol Assessment . Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for. TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided financial results for fiscal year 2024 and provided a corporate update.Innate Immune Agonists: TuHURA's IFx technology utilizes a proprietary plasmid DNA or messenger RNA  which, when introduced into or targeted to a tumor, results in the expression of a highly immunogenic gra","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYQNZ168.SGD","LU2039709279.SGD","IE000M9KFDE8.USD","LU0208291251.USD","LU1061106388.HKD","BK4526","QID","IE00B12V2V27.USD","NVIW.SI","USJW.SI","LU1934455194.USD","TQQQ","BK4534","LU0106261372.USD","LU1066051498.USD","LU0265550946.USD","LU0266013472.USD","BK4516","SQQQ","SG9999013999.USD","BK4509","PFS",".IXIC","LU2112291526.USD","NQmain","QLD","LU1571399168.USD","LU0265550359.USD","TSYW.SI","MNQmain","SG9999011746.SGD","TME","MRK","IE00B2B36J28.USD","BK4232","LU1917777945.USD","LU1066051225.USD","PSQ","LU1929549753.HKD","IE00BSNM7G36.USD","USAW.SI","IE00BN8TJ469.HKD","LU1069347547.HKD","SG9999015358.SGD","HURA","R","01698","BK4588","BK4531"],"gpt_icon":1},{"id":"2524118629","title":"Provident Financial Services, Inc. Schedules First Quarter Earnings Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2524118629","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524118629?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:00","pubTimestamp":1743508800,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., April  01, 2025  (GLOBE NEWSWIRE) -- Provident Financial Services, Inc. (NYSE: PFS) announced that it expects to release financial results for the quarter ended March 31, 2025 on Thursda","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053290/25661/en/Provident-Financial-Services-Inc-Schedules-First-Quarter-Earnings-Conference-Call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4581","BK4588","BK4144","BK4195","PFS","BK4585","BK4590","ET","BK4561"],"gpt_icon":0},{"id":"2524194196","title":"Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2524194196","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524194196?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053162/0/en/Tovecimig-CTX-009-Meets-Primary-Endpoint-in-the-Ongoing-Randomized-Phase-2-3-Study-in-Patients-with-Biliary-Tract-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","PFS","BK4139","BK4211","BK4092","BTC","IE00B19Z3581.USD","BK4161","OS","CMPX","BK4097","SD","BK4213","PR","PD","CR","BK4195","IE00B19Z3B42.SGD","IE0002270589.USD","LU1169590202.USD","IE00B7SZLL34.SGD","ORR","NE","BK4023"],"gpt_icon":0},{"id":"2524903020","title":"Cavalier Resources’ Revised PFS Indicates Strong Financial Prospects for Crawford Gold Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2524903020","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524903020?lang=en_us&edition=fundamental","pubTime":"2025-04-01 05:54","pubTimestamp":1743458053,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Cavalier Resources Limited ( ($AU:CVR) ). Cavalier Resources Limited announced a revised Pre-Feasibility Study ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cavalier-resources-revised-pfs-indicates-strong-financial-prospects-for-crawford-gold-project?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cavalier-resources-revised-pfs-indicates-strong-financial-prospects-for-crawford-gold-project?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2523092138","title":"TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523092138","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523092138?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:20","pubTimestamp":1743434400,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or af","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052498/0/en/TIVDAK-tisotumab-vedotin-Approved-by-European-Commission-for-Previously-Treated-Recurrent-or-Metastatic-Cervical-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ57979304.SGD","BK4599","LU0225284248.USD","IE0002270589.USD","LU1894683264.USD","LU0234572021.USD","BK4107","LU0321505439.SGD","LU0053666078.USD","BK4550","LU1066051498.USD","LU1883839398.USD","LU0306806265.USD","PFS","LU0122379950.USD","LU1057294990.SGD","SG9999003800.SGD","LU0170899867.USD","LU0058720904.USD","BK4201","MAA","BK4592","BK4080","EC","BK4581","IE00B19Z3581.USD","BK4231","BK4585","IE00BLSP4452.SGD","SG9999001176.USD","BK4534","LU0321505868.SGD","L","ORR","IE00BBT3K403.USD","BK4097","IE000M9KFDE8.USD","LU0868494617.USD","BK4533","SG9999011175.SGD","SG9999013999.USD","BK4007","IE00B19Z3B42.SGD","LU0289739699.SGD","SG9999002224.SGD","OS","LU0985481810.HKD","ADC"],"gpt_icon":1},{"id":"2523958946","title":"DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523958946","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523958946?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., March 31, 2025----The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU  in combination with a fluoropyrimidine chemotherapy  and Merck’s  anti-PD-1 therapy KEYTRUDA  versus trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive  gastric or gastroesophageal junction  cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will be randomized to either ENHERTU plus fluoropyrimidine or trastuzumab plus platinum-based chemotherapy.Gastric cancer is associated with a poor prognosis, particularly in advanced stages of the disease where the five-year survival rate is 5% to 10%.1 Current recommended first-line treatment for HER2 positive advanced gastric cancer with PD-L1 CPS ≥1 is trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab.2,3 New treatment strategies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/destiny-gastric05-phase-3-trial-120000580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","IE00B7SZL793.SGD","DSKYF","AEIS","BK4007","PFS","BK4080","PBD","DSNKY","BK4211","BK4231","BK4225","BK4203","IE00B66KJ199.SGD","HR","BK4195","ADC","IE00B19Z4B17.USD","BK4157"],"gpt_icon":0},{"id":"2523174849","title":"Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2523174849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523174849?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052133/0/en/Avacta-Provides-Business-Update-for-the-First-Quarter-of-2025-Outlining-Progress-Against-Strategic-Objectives.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","PFS","BK4211","BK4195","PRGS","BK4097"],"gpt_icon":0},{"id":"2523884919","title":"Hot Chili Announces PFS for Huasco Water & MOU for Seawater Supply to Costa Fuego","url":"https://stock-news.laohu8.com/highlight/detail?id=2523884919","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523884919?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:00","pubTimestamp":1743415200,"startTime":"0","endTime":"0","summary":"PERTH, Australia, March 31, 2025 /PRNewswire/ - Hot Chili Limited     is pleased to announce the results of a Pre-Feasibility Study  for the Company's subsidiary Huasco Water, an 80%-owned entity that controls strategic water assets in the Huasco Valley of Chile.Strong Economics for a Large, Multi-User, Water Business. Stage 2 Water SupplyPFS for 1,300 L/s of Potential Desalinated Water Supply: Post-tax NPV8% of US$958 million and IRR of 19%. Start-up capital cost for desalinated water supply estimated at US$1.4 billion with a 4 year payback. Stage 3 Conceptual Study for 2,300 L/s of Potential Desalinated Water Supply: Post-tax NPV8% of approximately US$1.3 billion andIRR of around 19%. Expansion capital cost for desalinated water supply estimated at US$1.9 billion with a 3.5 year payback. Only Active Maritime License:HW Aguas para El Huasco SpA , a joint venture between Hot Chili  and Compaia Minera Del Pacifico , is the only company with permitted access to supply seawater in the Hua","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/hot-chili-announces-pfs-huasco-100000515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hot-chili-announces-pfs-huasco-100000515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PEA.AU","BK7110","HCH.AU","PFS","EIS","BK4195","HHLKF","BK4211","BK4015","EIA","IRR"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2025-07-24","symbol":"PFS","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.5,"defaultRemindTime":1753344000000,"name":null,"time":"Pre-Market","dateTimestamp":1753329600000,"actualEps":null},{"date":"2025-05-16","symbol":"PFS","amount":0.24,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-16","defaultRemindTime":1747402200000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-16","currency":"USD","dateTimestamp":1747368000000,"payDate":"2025-05-30"},{"date":"2025-04-24","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.47,"defaultRemindTime":1745524800000,"name":null,"time":"Post Market","dateTimestamp":1745467200000,"actualEps":null},{"date":"2025-02-14","symbol":"PFS","amount":0.24,"announcedDate":"2025-01-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-14","defaultRemindTime":1739543400000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-28","payableDate":"2025-02-14","currency":"USD","dateTimestamp":1739509200000,"payDate":"2025-02-28"},{"market":"US","date":"2025-01-28","symbol":"PFS","fiscalQuarterEnding":"2024/12","expectedEps":0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738040400000,"reportTimeType":"post","actualEps":0.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2015-08-12","recordDate":"2015-08-14","paymentDate":"2015-08-28","value":0.16,"currency":"USD"},{"executeDate":"2015-11-10","recordDate":"2015-11-13","paymentDate":"2015-11-27","value":0.17,"currency":"USD"},{"executeDate":"2016-02-10","recordDate":"2016-02-12","paymentDate":"2016-02-26","value":0.17,"currency":"USD"},{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"},{"executeDate":"2016-08-11","recordDate":"2016-08-15","paymentDate":"2016-08-31","value":0.18,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1429,"buy":0.7143,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7143,"analysts":7,"updateTime":1750996800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2025-07-17","current":16.240459,"percent":0.774659,"low":6.410614,"twenty":8.954399,"median":10.710589,"eighty":16.928687,"high":33.979783,"avg":13.452102,"sd":6.422763,"marketCap":2394996736},"quantilePoints":[{"date":"2020-07-24","current":9.601469,"twenty":13.098537,"median":17.431245,"eighty":19.049774,"marketCap":928212371},{"date":"2020-07-31","current":10.146984,"twenty":13.0648,"median":17.422118,"eighty":19.049774,"marketCap":878647633},{"date":"2020-08-07","current":10.689643,"twenty":13.048711,"median":17.403942,"eighty":19.049774,"marketCap":925637580},{"date":"2020-08-14","current":10.527035,"twenty":13.031177,"median":17.388517,"eighty":19.049774,"marketCap":911556975},{"date":"2020-08-21","current":9.599052,"twenty":13.008395,"median":17.362339,"eighty":19.049774,"marketCap":831201106},{"date":"2020-08-28","current":9.947973,"twenty":12.988694,"median":17.334295,"eighty":19.049774,"marketCap":861414913},{"date":"2020-09-04","current":10.155841,"twenty":12.944965,"median":17.31872,"eighty":19.049774,"marketCap":879414627},{"date":"2020-09-11","current":9.509966,"twenty":12.926046,"median":17.247931,"eighty":19.049774,"marketCap":823486942},{"date":"2020-09-18","current":9.539661,"twenty":12.903594,"median":17.204455,"eighty":19.049774,"marketCap":826058330},{"date":"2020-09-25","current":8.916057,"twenty":12.85637,"median":17.165483,"eighty":19.049774,"marketCap":772059186},{"date":"2020-10-02","current":9.457999,"twenty":12.836682,"median":17.1464,"eighty":19.049774,"marketCap":818987014},{"date":"2020-10-09","current":9.777225,"twenty":12.825762,"median":17.106994,"eighty":19.030829,"marketCap":846629433},{"date":"2020-10-16","current":9.658443,"twenty":12.807943,"median":17.057235,"eighty":18.996004,"marketCap":836343881},{"date":"2020-10-23","current":10.222656,"twenty":12.774984,"median":17.027417,"eighty":18.941136,"marketCap":885200250},{"date":"2020-10-30","current":10.595048,"twenty":12.75677,"median":16.971439,"eighty":18.91343,"marketCap":872343311},{"date":"2020-11-06","current":10.696549,"twenty":12.723452,"median":16.947615,"eighty":18.891695,"marketCap":880700321},{"date":"2020-11-13","current":13.674488,"twenty":12.723452,"median":16.898923,"eighty":18.890505,"marketCap":1125888942},{"date":"2020-11-20","current":14.639195,"twenty":12.723452,"median":16.877422,"eighty":18.890505,"marketCap":1205318094},{"date":"2020-11-27","current":15.191794,"twenty":12.723452,"median":16.856678,"eighty":18.890505,"marketCap":1250816345},{"date":"2020-12-04","current":16.053474,"twenty":12.723452,"median":16.820466,"eighty":18.876273,"marketCap":1321762772},{"date":"2020-12-11","current":16.072206,"twenty":12.723452,"median":16.79439,"eighty":18.876273,"marketCap":1323305085},{"date":"2020-12-18","current":16.222063,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1335643594},{"date":"2020-12-24","current":16.718466,"twenty":12.723452,"median":16.730308,"eighty":18.876273,"marketCap":1376514905},{"date":"2020-12-31","current":16.821493,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1384997630},{"date":"2021-01-08","current":18.095281,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1489874956},{"date":"2021-01-15","current":17.992254,"twenty":12.723452,"median":16.744122,"eighty":18.876273,"marketCap":1481392232},{"date":"2021-01-22","current":18.142111,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1493730740},{"date":"2021-01-29","current":14.720538,"twenty":12.723452,"median":16.78893,"eighty":18.876273,"marketCap":1427170886},{"date":"2021-02-05","current":15.094115,"twenty":12.723452,"median":16.757917,"eighty":18.876273,"marketCap":1463389586},{"date":"2021-02-12","current":15.571023,"twenty":12.723452,"median":16.755695,"eighty":18.876273,"marketCap":1509626224},{"date":"2021-02-19","current":15.626662,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1515020498},{"date":"2021-02-26","current":16.079724,"twenty":12.723452,"median":16.714233,"eighty":18.876273,"marketCap":1558945304},{"date":"2021-03-05","current":17.794179,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1725163471},{"date":"2021-03-12","current":18.789768,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1821686827},{"date":"2021-03-19","current":18.215526,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1766013442},{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":15.595237,"twenty":8.579877,"median":10.368229,"eighty":12.928956,"marketCap":1870555147},{"date":"2024-06-07","current":14.804645,"twenty":8.579877,"median":10.368229,"eighty":12.944965,"marketCap":1775728393},{"date":"2024-06-14","current":14.479745,"twenty":8.579877,"median":10.368229,"eighty":12.974084,"marketCap":1736758494},{"date":"2024-06-21","current":14.609705,"twenty":8.578848,"median":10.365511,"eighty":13.001042,"marketCap":1752346453},{"date":"2024-06-28","current":15.541087,"twenty":8.578848,"median":10.365511,"eighty":13.028149,"marketCap":1864060164},{"date":"2024-07-05","current":15.400297,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":1847173207},{"date":"2024-07-12","current":17.403852,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":2087487584},{"date":"2024-07-19","current":19.212466,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2304420021},{"date":"2024-07-26","current":32.346496,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2473083727},{"date":"2024-08-02","current":29.436843,"twenty":8.578848,"median":10.365511,"eighty":13.071794,"marketCap":2250623276},{"date":"2024-08-09","current":28.842709,"twenty":8.578848,"median":10.365511,"eighty":13.113823,"marketCap":2205198173},{"date":"2024-08-16","current":30.822445,"twenty":8.578848,"median":10.365511,"eighty":13.134508,"marketCap":2356560887},{"date":"2024-08-23","current":32.631515,"twenty":8.578848,"median":10.365511,"eighty":13.176313,"marketCap":2494875092},{"date":"2024-08-30","current":32.546181,"twenty":8.578848,"median":10.365511,"eighty":13.215944,"marketCap":2488350837},{"date":"2024-09-06","current":31.197913,"twenty":8.578848,"median":10.365511,"eighty":13.228055,"marketCap":2385267609},{"date":"2024-09-13","current":31.300313,"twenty":8.578848,"median":10.365511,"eighty":13.30073,"marketCap":2393096715},{"date":"2024-09-20","current":32.187781,"twenty":8.578848,"median":10.365511,"eighty":13.316627,"marketCap":2460948967},{"date":"2024-09-27","current":31.283246,"twenty":8.578848,"median":10.365511,"eighty":13.405115,"marketCap":2391791864},{"date":"2024-10-04","current":30.429912,"twenty":8.578848,"median":10.365511,"eighty":13.64376,"marketCap":2326549315},{"date":"2024-10-11","current":32.136581,"twenty":8.578848,"median":10.365511,"eighty":13.888037,"marketCap":2457034414},{"date":"2024-10-18","current":33.314182,"twenty":8.578848,"median":10.365511,"eighty":14.144229,"marketCap":2547069132},{"date":"2024-10-25","current":31.88058,"twenty":8.578848,"median":10.365511,"eighty":14.323115,"marketCap":2437461649},{"date":"2024-11-01","current":26.079311,"twenty":8.578848,"median":10.365511,"eighty":14.468915,"marketCap":2459644116},{"date":"2024-11-08","current":29.303632,"twenty":8.578848,"median":10.365511,"eighty":14.501405,"marketCap":2763742765},{"date":"2024-11-15","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.577215,"marketCap":2792450197},{"date":"2024-11-22","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.642195,"marketCap":2792450197},{"date":"2024-11-29","current":29.220619,"twenty":8.578848,"median":10.365511,"eighty":14.720538,"marketCap":2755913466},{"date":"2024-12-06","current":28.72254,"twenty":8.578848,"median":10.365511,"eighty":14.772155,"marketCap":2708937668},{"date":"2024-12-13","current":28.16912,"twenty":8.578848,"median":10.365511,"eighty":14.811522,"marketCap":2656742337},{"date":"2024-12-20","current":26.370502,"twenty":8.578848,"median":10.365511,"eighty":14.879507,"marketCap":2487107512},{"date":"2024-12-27","current":26.107627,"twenty":8.578848,"median":10.365511,"eighty":14.930682,"marketCap":2462314730},{"date":"2025-01-03","current":26.19064,"twenty":8.578848,"median":10.365511,"eighty":15.008136,"marketCap":2470144030},{"date":"2025-01-10","current":24.945443,"twenty":8.578722,"median":10.36461,"eighty":15.045075,"marketCap":2352704535},{"date":"2025-01-17","current":26.730225,"twenty":8.578722,"median":10.36461,"eighty":15.087294,"marketCap":2521034477},{"date":"2025-01-24","current":26.232147,"twenty":8.578722,"median":10.36461,"eighty":15.170193,"marketCap":2474058679},{"date":"2025-01-31","current":20.975271,"twenty":8.578722,"median":10.36461,"eighty":15.27162,"marketCap":2423168232},{"date":"2025-02-07","current":21.686872,"twenty":8.578722,"median":10.36461,"eighty":15.43113,"marketCap":2505375878},{"date":"2025-02-14","current":21.065633,"twenty":8.578722,"median":10.36461,"eighty":15.506431,"marketCap":2433607298},{"date":"2025-02-21","current":20.489576,"twenty":8.578722,"median":10.36461,"eighty":15.601522,"marketCap":2367058251},{"date":"2025-02-28","current":20.614008,"twenty":8.578722,"median":10.36461,"eighty":15.733365,"marketCap":2381433247},{"date":"2025-03-07","current":19.427996,"twenty":8.578596,"median":10.36371,"eighty":15.909803,"marketCap":2244419279},{"date":"2025-03-14","current":19.373214,"twenty":8.58723,"median":10.384564,"eighty":16.110435,"marketCap":2238090520},{"date":"2025-03-21","current":19.113398,"twenty":8.626133,"median":10.390798,"eighty":16.250162,"marketCap":2208075312},{"date":"2025-03-28","current":19.282843,"twenty":8.679674,"median":10.422436,"eighty":16.324736,"marketCap":2227650448},{"date":"2025-04-04","current":17.498022,"twenty":8.697705,"median":10.433885,"eighty":16.538637,"marketCap":2021459018},{"date":"2025-04-11","current":16.594315,"twenty":8.729831,"median":10.450581,"eighty":16.720339,"marketCap":1917058294},{"date":"2025-04-17","current":17.498022,"twenty":8.74788,"median":10.472646,"eighty":16.838352,"marketCap":2021459018},{"date":"2025-04-25","current":14.654875,"twenty":8.784492,"median":10.48224,"eighty":16.926427,"marketCap":2161169063},{"date":"2025-05-02","current":15.142189,"twenty":8.798752,"median":10.513034,"eighty":16.926427,"marketCap":2233033814},{"date":"2025-05-09","current":15.159534,"twenty":8.804878,"median":10.526765,"eighty":16.926427,"marketCap":2235591607},{"date":"2025-05-16","current":15.505075,"twenty":8.82909,"median":10.533858,"eighty":16.926427,"marketCap":2286548985},{"date":"2025-05-23","current":14.787412,"twenty":8.855843,"median":10.556785,"eighty":16.926427,"marketCap":2180714431},{"date":"2025-05-30","current":14.884872,"twenty":8.8606,"median":10.572534,"eighty":16.926427,"marketCap":2195087025},{"date":"2025-06-06","current":14.619071,"twenty":8.875633,"median":10.60779,"eighty":16.926427,"marketCap":2155889043},{"date":"2025-06-13","current":15.000053,"twenty":8.887975,"median":10.619572,"eighty":16.926427,"marketCap":2212072818},{"date":"2025-06-20","current":14.30011,"twenty":8.911603,"median":10.626285,"eighty":16.928687,"marketCap":2108851463},{"date":"2025-06-27","current":15.850617,"twenty":8.946056,"median":10.641658,"eighty":16.928687,"marketCap":2337506362},{"date":"2025-07-03","current":16.710041,"twenty":8.946056,"median":10.65175,"eighty":16.928687,"marketCap":2464246506},{"date":"2025-07-11","current":16.648021,"twenty":8.954399,"median":10.683931,"eighty":16.928687,"marketCap":2455100310},{"date":"2025-07-17","current":16.240459,"twenty":8.954399,"median":10.710589,"eighty":16.928687,"marketCap":2394996736}],"updateTime":1752855394982}}}